Technetium Containing (at. No. 43; Tc) Patents (Class 534/14)
  • Patent number: 11083804
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 10, 2021
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Patent number: 10328164
    Abstract: The present invention relates to improved radiopharmaceutical compositions in sealed containers, where the container closure has an ETFE (ethylene-tetrafluoroethylene copolymer) coating. Also disclosed are kits for radiopharmaceutical preparation using the sealed containers, as well as methods of preparation of radiopharmaceuticals using the sealed containers.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: June 25, 2019
    Assignee: GE HEALTHCARE LIMITED
    Inventor: Stig Hemstad
  • Patent number: 9987379
    Abstract: A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Yanming Wang, Chunying Wu
  • Patent number: 9771203
    Abstract: An oxygen absorbing agent composition including at least one type of a compound having an indane skeleton represented by the following general formula (1) and a transition metal catalyst:
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: September 26, 2017
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Satoshi Okada, Shinichi Ikeda, Kenichiro Usuda, Shinpei Iwamoto
  • Patent number: 9028802
    Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 12, 2015
    Assignee: Koninklijke Philips N.V.
    Inventor: Frank Olaf Thiele
  • Patent number: 9028799
    Abstract: A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: May 12, 2015
    Inventor: Jianping Ruan
  • Patent number: 9017826
    Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: April 28, 2015
    Assignees: The University of Southern California, The Regents of the University of Michigan
    Inventors: Stephen R. Forrest, Jeramy D. Zimmerman, Mark E. Thompson, Viacheslav Diev, Kenneth Hanson
  • Patent number: 8940273
    Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: January 27, 2015
    Assignee: Mallinckrodt LLC
    Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
  • Publication number: 20150023878
    Abstract: The compounds of the invention are inhibitors of excitatory amino acid transporters (EAAT) that penetrate the blood-brain barrier to access the central nervous system. The compounds of the invention follow the structural formula: or a salt, ester or prodrug thereof, wherein X is a halogen, such as fluorine, or a radionuclide, such as fluorine-18. The compounds and methods described herein can be used for the treatment of, e.g., neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), ischemia, spinal cord injury, and traumatic brain injury in a patient (e.g., a human). The invention further provides compounds and methods for the synthesis and use of radiographic tracers to diagnose and follow the progression of such disorders.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 22, 2015
    Inventors: John M. Gerdes, Richard J. Bridges, Syed K. Ahmed, Sarjubhai Patel
  • Publication number: 20140371434
    Abstract: A radiotracer precursor for imaging of hypoxic tissues, a radiotracer and a method for preparing the same are revealed. The radiotracer precursor, DANI, includes a nitroimidazole functional group with a feature of retention in hypoxic tissues and a bifunctional ligand able to complex with radioisotopes. Thus DANI can be used to produce radiotracers stayed in hypoxic tissues and the radiotracers are applied to medical imaging of malignant tumor with hypoxic layer.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 18, 2014
    Inventors: SHOW-WEN LIU, YU CHANG, CHENG-FANG HSU, TSUNG-HSIEN CHIANG, SHENG-LUN LIN, CHIH-YUAN LIN
  • Publication number: 20140341805
    Abstract: A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 20, 2014
    Applicant: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
    Inventors: John W. BABICH, Craig ZIMMERMAN, John JOYAL, Kevin P. MARESCA, John MARQUIS, Genliang LU, Jian-cheng WANG, Shawn HILLIER
  • Publication number: 20140336368
    Abstract: A multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging.
    Type: Application
    Filed: November 18, 2011
    Publication date: November 13, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, HOSPICES CIVILS DE LYON
    Inventors: Delphine Felder-Flesch, Claire Billotey, Giuseppe Lamanna, Marc Janier, David Kriza
  • Patent number: 8840865
    Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: September 23, 2014
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
  • Patent number: 8834842
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 16, 2014
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Publication number: 20140248213
    Abstract: The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 4, 2014
    Applicants: CEDARS-SINAI MEDICAL CENTER, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Leland W. K. Chung, Dongfeng Pan
  • Publication number: 20140234216
    Abstract: The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 21, 2014
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Harriet Struthers, Viola Groehn, Simon Mensah Ametamey, Cindy Ramona Fischer
  • Patent number: 8778303
    Abstract: The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE at a 1:1 ratio with high affinity and exclusive specificity. Novel Duramycin-based radiopharmaceuticals and non-radioactively labeled compounds are disclosed herein. Such compounds facilitate detection of cell apoptosis and/or necrosis by binding to PtdE. The location of the bound compound can then be pinpointed using standard imaging techniques.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: July 15, 2014
    Assignee: The Medical College of Wisconsin, Inc.
    Inventor: Ming Zhao
  • Publication number: 20140186262
    Abstract: A novel gall bladder image agent which includes a radio-labelled MAG3-tri-galactosamine, and its preparation method, which includes reacting mercaptoacetyltriglycine (MAG3)-tri-galactosamine, SnF2 and Tc-99m in the presence of a phosphate buffer solution (at pH of from 10.0˜12.0) to obtain Tc-99m-MAG3-tri-galactosamine, when the MAG3-tri-galactosamine is MAG3-DCM-Lys(Gah-GalNAc)3 (where DCM represents a dicarboxymethyl group, and Gah represents a glycine-aminohexyl group), it obtains a labelling yield of at least 90%, and its specific radioactivity is at least 7.0×109 Bq/mg.
    Type: Application
    Filed: December 30, 2013
    Publication date: July 3, 2014
    Applicant: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
    Inventors: MEI-HUI WANG, HUNG-MAN YU, CHUAN-YI CHIEN, PING-YEN WANG, WUU-JYH LIN, KUN-LIANG LIN, JEN-TSUNG WANG
  • Patent number: 8747810
    Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: June 10, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: Ashfaq Mahmood, Alun G. Jones, Naengnoi Limpa-Amara, Yijie Peng, Zeynep Akgun
  • Publication number: 20140121361
    Abstract: Novel N3S1 chelator-folate derivatives, a preparation method thereof, and a composition for diagnosis and treatment of tumor including the same as an active ingredient are provided. The novel N3S1 chelator-folate derivatives or a pharmaceutically acceptable salt thereof are easily introduced into the cells using receptor binding to tumor expressing ?-folate receptor (?-FR). Accordingly, the folate derivatives, labeled with radioisotope such as technetium, or rhenium, can be advantageously used for the diagnosis and treatment of tumor using tumor imaging and irradiation from the isotope, and therefore, can be widely used for the purpose of labeling a variety of radiopharmaceuticals.
    Type: Application
    Filed: October 25, 2013
    Publication date: May 1, 2014
    Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Young-Don HONG, Sun Ju CHOI, So-Young LEE, Jae Cheong LIM, Dong Eun LEE
  • Publication number: 20140058071
    Abstract: The present invention describes peptidomimetic radiotracers. In particular, the present invention discloses fibrosis specific multimeric small-molecule peptidomimetic radiotracers.
    Type: Application
    Filed: August 21, 2012
    Publication date: February 27, 2014
    Inventors: Kumar Ranjan Bhushan, Preeti Misra
  • Publication number: 20140031533
    Abstract: A precursor used for labeling hepatocyte receptors and applied to radiotracers for imaging or pharmaceutical compositions for liver cancers is revealed. The precursor is a bifunctional compound. The bifunctional group includes a trisaccharide structure and a diamide dimercaptide (N2S2) ligand. The trisaccharide has high affinity to asialoglycoprotein receptors (ASGPR) on surfaces of hepatocytes while N2S2 ligand reacts with radioisotopes to form neutral complexes. Thus the precursor stays on surfaces of hepatocytes to provide radioisotope labeling or treatment effect of liver cancers.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Applicant: ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: SHOW-WEN LIU, YU CHANG, CHENG-FANG HSU, MING-CHE TSAI, TSUNG-HSIEN CHIANG, YUEH-FENG DENG, KUEI-LIN LU, CHIH-YUAN LIN, DA-MING WANG, CHING-YUN LI
  • Publication number: 20140010758
    Abstract: Compounds of the formulae, (I), wherein each variable is as defined herein are provided which are useful in (i) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable carrier, excipient, and/or diluent; (3) methods for inhibiting or treating prostrate cancer; and (4) methods for blocking or destabilizing neovasculature of a tumor.
    Type: Application
    Filed: November 10, 2011
    Publication date: January 9, 2014
    Applicants: THE REGEANTS OF THE UNIVERSITY OF CALIFORNIA, WASHINGTON STATE UNIVERSITY
    Inventors: Clifford E. Berkmam, Henry F. Vanbrocklin
  • Publication number: 20130302245
    Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.
    Type: Application
    Filed: April 17, 2013
    Publication date: November 14, 2013
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: David J. YANG, Chang-sok OH, Saady KOHANIM, Dongfang YU, Richard MENDEZ, E. Edmund KIM
  • Patent number: 8562945
    Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 22, 2013
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
  • Patent number: 8545809
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 1, 2013
    Assignee: Immunomedics, Inc.
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Patent number: 8512675
    Abstract: The present invention relates to novel histidine derivates that can be used for the labeling of biomolecules with radioactive metal tricarbonyls. The new derivatives have a histidine that is derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and N? and at least protected at the N? and optionally at the N?; or derivatized at the N?; or derivatized at the N?; or derivatized at the N? and N?; or at least protected at the N? and optionally at the N?.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: August 20, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Roger Alberto, Jae Kyoung Pak
  • Publication number: 20130195756
    Abstract: An embodiment of the invention comprises a ligand of Formula I wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n(NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10. Also included are an imaging agent comprising a compound of Formula I complexed to 99mTc and their method of use to image a subject having a target site using single photon emission computed tomography (SPECT).
    Type: Application
    Filed: January 31, 2012
    Publication date: August 1, 2013
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
  • Publication number: 20130171067
    Abstract: The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same.
    Type: Application
    Filed: November 24, 2011
    Publication date: July 4, 2013
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Yves Guminski, Thierry Imbert, Sabrina Pesnel, Nicolas Guilbaud, Alain Le Pape, Stéphanie Lerondel
  • Publication number: 20130165631
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Application
    Filed: July 18, 2012
    Publication date: June 27, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • Publication number: 20130149249
    Abstract: The present invention provides novel in vivo imaging agents useful for detecting the presence of mycobacteria using in vivo imaging methods. Also provided by the present invention is a precursor compound useful in the synthesis of the in vivo imaging agents of the invention, and a method to obtain the in vivo imaging agent of the invention using said precursor compound. Methods of in vivo imaging and diagnosis in which the in vivo imaging agent of the invention finds use are also provided.
    Type: Application
    Filed: August 22, 2011
    Publication date: June 13, 2013
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Vijaya Raj Kuniyil Kulangara, Ravi Hegde
  • Publication number: 20130131327
    Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
    Type: Application
    Filed: January 15, 2013
    Publication date: May 23, 2013
    Applicant: Mallinckrodt LLC
    Inventor: Mallinckrodt LLC
  • Patent number: 8372379
    Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
    Type: Grant
    Filed: November 23, 2007
    Date of Patent: February 12, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
  • Patent number: 8367811
    Abstract: A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as 188Re, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: February 5, 2013
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Tsai-Yueh Luo, I-Chung Tang, Jian-Wen Chen, Kwei-Luen Hsu, Yu-Lung Wu, Te-Sheng Liang, Chang-Mau Sheng, Jin-Jenn Lin, Ching-Jun Liou, Jyh-Daw Sheu
  • Patent number: 8357350
    Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: January 22, 2013
    Assignee: General Electric Company
    Inventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Kenneth Michael Fish, Nicole Evelyn Barnhardt, John V. Frangioni, Carrie S. Vooght
  • Patent number: 8354512
    Abstract: A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: January 15, 2013
    Assignee: National Chiao Tung University
    Inventors: Yun-Ming Wang, Ting-Jung Chen
  • Publication number: 20120321560
    Abstract: This invention relates to a chemistry branch, particularly to the field of compounds' organic synthesis that belongs to the aromatic bicyclic or naphthalene category, used in the detection of amyloid sheets. These new naphthalene derivatives have a general formula: Wherein R represents mutually independent groups. In I: R1:-alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O—R4, R3:—COOH, —OH, —SH, —NH2, -alkyl-NH-alkyl-N-dithiocarbamate alkaline earth metal salts, R4: H, succinimidyl group, R2: —H,-alkyl. In II: R1: -alkyl, -alkylenyl-halide-alkylenyl-hydroxyl-alkylenyl-O-aryl, —O-alkylsulfonate alkylenyl, R2: -halide-alkylenyl-O-aryl, -alkylenyl-O-alkylsulfonate, -alkylenyl-halide-, —CH(O), —HC?C(CN)2, —HC?CHNO2, -alkylenyl-NH2, -alkylenyl-NH-alkyl, -alkylenyl-alkyl-N-dithiocarbamate alkaline salts. The terms “alkyl” and “alkylenyl” refer to linear or branched aliphatic chains, preferably from 1 to 4 carbon atoms and the term halide to fluorine, bromine or iodine.
    Type: Application
    Filed: April 17, 2010
    Publication date: December 20, 2012
    Inventors: Marquiza Sablón Carrazana, Chryslaine Rodriguez-Tanty, Alejandro Perera Pintado, Suchitil Rivera Marrero, Rafaela Perez Perera, Rosa Maria López Barroso, Anais Prats Capote, Hermán Vélez Castro, Carlos Serafin Pérez Martínez, Pedro Valdés Sosa
  • Patent number: 8329879
    Abstract: H3LMN series compounds used as radioactive agents for treatment of liver cancer and a manufacturing method thereof are revealed. 2-thioethylamine hydrochloride is reacted with triphenylmethanol for protection of thiol to obtain 2-[(triphenylmethyl)thio]ethylamine. Then obtain N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide by a transamidation reaction between 2-[(triphenylmethyl)thio]ethylamine and chloroactyl chloride. Next produce a amine-amide-thiol ligand-N-[2-((triphenylmethyl)thio)ethyl][2-((triphenylmethyl)thio)ethylamino]acetamide by a substitution reaction of N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide and 2-[(triphenylmethyl)thio]ethylamine. After respective reaction with 1-bromotetradecane, 1-bromohexadecane and ethyl 16-bromohexadecanoate, H3LMN series compounds are obtained. These amine-amide-dithiols quadridentate ligands can react with MO3+ (M=Tc or Re) to produce electrically neutral complexes.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: December 11, 2012
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Show-Wen Liu, Cheng-Hsien Lin, Tsyh-Lang Lin, Cheng-Fang Hsu
  • Publication number: 20120277409
    Abstract: The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one liner covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by said linker. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a linker to a polysaccharide to obtain an intermediate and by conjugating said intermediate to a metal to form a polysaccharide conjugate. This conjugate has a higher relaxivity, so it is suitable to be used as a contrast medium for hybrid camera.
    Type: Application
    Filed: April 10, 2012
    Publication date: November 1, 2012
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TAIWAN HOPAX CHEMS. MFG. CO., LTD.
    Inventors: DAVID J. YANG, YEN-SHIAN WU, HSIEN-FAN CHEN, YUN-CHI LO, NING TSAO, CHIH-WEI HSU
  • Publication number: 20120258043
    Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 11, 2012
    Applicant: BRACCO SUISSE S.A.
    Inventors: Ramachandran RANGANATHAN, Kondareddiar RAMALINGAM, Radhakrishna PILLAI, Edmund R. MARINELLI, Rolf E. SWENSON
  • Patent number: 8278448
    Abstract: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the use of 99mTc radiopharmaceuticals of the invention for SPECT imaging.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: October 2, 2012
    Assignee: GE Healthcare Limited
    Inventor: Rajiv Bhalla
  • Publication number: 20120244074
    Abstract: The present invention provides alternative in vivo imaging agents suitable for use in the detection of ?v?6 expressed in a subject. The invention also provides a method for obtaining said in vivo imaging agents, and use of the in vivo imaging agents in determining ?v?6 expressed in a subject.
    Type: Application
    Filed: December 16, 2010
    Publication date: September 27, 2012
    Inventor: Magne Solbakken
  • Publication number: 20120213702
    Abstract: The present invention relates to aminopeptidase N (APN) inhibitor conjugates of formula I wherein W is a —CO— or an —SO2— group and at least one of R1 or R2 represents (OCH2—CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and the other represents an alkoxy group or OH, and wherein R3, R3? and R3? is independently selected from an alkoxy group or (OCH2—CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and R4 is selected from the group comprising: wherein R is an alkyl group. Furthermore, the present invention relates to a diagnostic and/or pharmaceutical composition comprising the conjugate of the invention.
    Type: Application
    Filed: August 31, 2010
    Publication date: August 23, 2012
    Inventors: Christoph Bremer, Carsten Höltke
  • Patent number: 8247538
    Abstract: Disclosed herein is a method for the preparation of radioisotope-labeled compounds using CNT. It comprises filling the carbon nanotube with a radioisotope; and labeling a physiologically active material with the radioisotope charged in the carbon nanotube. Taking advantage of CNT, the method can prepare a radioisotope-labeled compound invention at a high yield and in a simple manner. Also, the radioisotope, when remaining unreacted, can be recovered by the filtration of the CNT, thereby achieving the prevention of radioactive contamination and the reduction of radioactive waste. Further, the radioisotope-labeled compound is useful as a contrast medium for imaging the hepatobiliary system.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 21, 2012
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Sang Hyun Park, Hui Jeong Gwon, Myung Woo Byun
  • Publication number: 20120208988
    Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
    Type: Application
    Filed: November 11, 2011
    Publication date: August 16, 2012
    Applicant: MOLECULAR INSIGHTS PHARMACEUTICALS, INC.
    Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
  • Publication number: 20120207674
    Abstract: The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99mTcO4, which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.
    Type: Application
    Filed: February 15, 2011
    Publication date: August 16, 2012
    Applicant: KUWAIT UNIVERSITY
    Inventor: FATMA JASSAB FALEH MARZOOQ AL-SAEEDI
  • Patent number: 8232360
    Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: July 31, 2012
    Assignee: Research Foundation of State University of N.Y.
    Inventors: Nicole S. Sampson, Kathlyn A. Parker
  • Patent number: 8211401
    Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: July 3, 2012
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
  • Patent number: RE44338
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 2, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
  • Patent number: RE44354
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 9, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky